AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02560792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Affect Condition
Description: Participants read: Most people exercising at this intensity say that it doesn't feel very good, and that it makes them feel tired and not so positive, and not very relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to negative feelings, and what specifically about this exercise might make you, personally, feel bad.
Study NCT02560792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Condition
Description: Participants receive no information about affective response
Study NCT00581789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib, sunitinib
Description: erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
Study NCT03044288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This is a strip made of a newly developed adhesive. This adhesive might in the future be part of an ostomy product.
Study NCT03044288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive strip
Description: this is a standard adhesive strip (hydrocolloid). This adhesive is currently used in marketed ostomy devices.
Study NCT00449007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 6 months
Study NCT00153166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin/placebo
Description: atorvastatin 80 mg orally once daily and matching placebo orally twice daily
Study NCT00449007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion
Description: 6 months
Study NCT03387774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
Study NCT03387774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
Study NCT01169259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
Study NCT01169259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo
Study NCT01169259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo
Study NCT01169259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT01169259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT03007589 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: otc sunscreens
Description: Sunscreens of various SPF levels and ingredients
Study NCT03007589 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sun protection fabrics
Description: fabrics
Study NCT03007589 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optical Filters
Description: Optical band pass or long pass filters or surfaces/mirrors used in solar simulators
Study NCT00153166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone/placebo
Description: pioglitazone 30 mg orally once daily and matching placebo orally once daily
Study NCT00153166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone/placebo
Description: pioglitazone 30 mg orally once daily and matching placebo orally once daily
Study NCT00153166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo/placebo
Description: placebo orally three times daily
Study NCT00153166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/placebo
Description: placebo orally three times daily
Study NCT01863862 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy or radiotherapy
Description: 50 Gy, 2 Gy per fraction with simultaneous 5-Fu and leucovorin or 5 x 5 Gy for patients unfit for chemotherapy.~Patients with complete clinical response 8-10 weeks after radiotherapy will be closely observed and rescue surgery will be performed in a case of local recurrence.~Patients with persistent tumour 8-10 weeks after radiotherapy will undergo transanal endoscopic microsurgery or total mesorectal excision. After transanal endosciopic microsurgery, patients with ypT0-1 disease and negative surgical margins will be closely observed and rescue total mesorectal excision will be performed in a case of local recurrence; those with ypT2-3 disease or with positive margin will undergo immediate conversion to total mesorectal excision.
Study NCT00041015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride
Study NCT04179058 — intervention group
Intervention type: OTHER
Intervention: Follow-up
Description: Clinical data, radiological data and laboratory tests follow-up
Study NCT00319696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg
Description: Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)
Study NCT00319696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg
Description: Bosentan 125-mg oral tablets administered b.i.d. (target dose)
Study NCT02275962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877
Study NCT02275962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Study NCT04558450 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: carotid-femoral pulse-wave velocity
Description: early vascular aging tests
Study NCT00525213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rob 803
Description: two capsules per day during 12 weeks
Study NCT03387774 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy
Description: Patients in both arms received Intensity Modulated Radiation Therapy:~All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose was 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
Study NCT03387774 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Patients in both arms received Intensity Modulated Radiation Therapy:~All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose was 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
Study NCT03387774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Patients in the experimental group were received ulinastatin:~Ulinastatin (UTI): ulinastatin was intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline every time, 3 times every radiation day, and until the end of radiotherapy.
Study NCT01524458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per-Oral Endoscopic Myotomy
Description: To perform myotomy for lower esophageal sphincter using endoscope through a long submucosal tunnel
Study NCT00375310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Sorafenib
Description: Gemcitabine is given IV~Sorafenib is given orally of varying doses:~1. Sorafenib 200 mg po qd ( during combination therapy)~2. Sorafenib 400 mg po qd ( during combination therapy)~3. Sorafenib 400 mg po bid ( during combination therapy)
Study NCT00375310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 1.8 Gy CTV daily for 5 weeks
Study NCT02229292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Active group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure.
Study NCT01094483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400
Description: naproxen 500 mg/esomeprazole 20 mg oral tablet
Study NCT02229292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure.
Study NCT03488485 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Direct Acting Antivirals
Description: DAAs given in patients with viremic chronic hepatitis C
Study NCT01094483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: Asprin 81 mg enteric coated tablet
Study NCT01094483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASA
Description: Asprin 81 mg enteric coated tablet
Study NCT01094483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01224899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left cervico-thoracic sympathetic blockade
Description: Left cervico-thoracic sympathetic blockade by videothoracoscopic clipping under general anesthesia and single-lumen orotracheal intubation in semi-sitting position.
Study NCT04760795 — intervention group
Intervention type: OTHER
Intervention: PTSD Check List (PCL) scale
Description: PTSD Check List (PCL) scale will be realized to evaluated post-traumatic stress disorder.
Study NCT04760795 — intervention group
Intervention type: OTHER
Intervention: Brief COPE scale
Description: Brief COPE scale dispositional version will be realized to evaluated usual coping strategies. It was assessed during the teleconsultations and post containment.
Study NCT04760795 — intervention group
Intervention type: OTHER
Intervention: GAD-7 (Generalized Anxiety Disorder) scale (during containment)
Description: GAD 7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
Study NCT04760795 — intervention group
Intervention type: OTHER
Intervention: Analog scale
Description: Analog scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
Study NCT04760795 — intervention group
Intervention type: OTHER
Intervention: GAD-7 (Generalized Anxiety Disorder) scale (post containment)
Description: GAD-7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during post containment.
Study NCT04760795 — intervention group
Intervention type: OTHER
Intervention: Big Five Inventory (BFI) scale
Description: Big Five Inventory (BFI) will be realized to evaluated personality.
Study NCT04760795 — intervention group
Intervention type: OTHER
Intervention: Relationship Scales Questionnaire (RSQ)
Description: Relationship Scales Questionnaire (RSQ) will be realized to evaluated attachment style.
Study NCT03156153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
Study NCT03156153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
Study NCT02190591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peanut Labor Ball
Description: Peanut Labor Ball
Study NCT00525213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two capsules per day during 12 weeks
Study NCT02116595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high or low acid diet
Description: high or low acid diets
Study NCT02116595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high or low acid diet
Description: high or low acid diets
Study NCT01535222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO-2010
Description: MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
Study NCT01535222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available NaCl
Study NCT02728999 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Steep Trendelenburg
Description: •Subjects who undergo steep Trendelenburg will remain in 30 degrees of Trendelenburg, and the da Vinci robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure.
Study NCT02728999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decreased Trendelenburg
Description: •Subjects who undergo decreased Trendelenburg will be taken out of Trendelenburg to the minimal angle possible that enables adequate visualization, as determined by the primary surgeon, at which time robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure.
Study NCT01447017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPK-060
Description: DPK-060 2% ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
Study NCT01447017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DPK-060 ear drops
Description: Placebo for DPK-060 ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
Study NCT00870662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFS System
Description: AFS System with patient specific flow rate
Study NCT00127985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-methyl-prednisolone
Description: iv, 2 mg/kg/day, qid
Study NCT06666582 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel and ramucirumab
Description: Second-line treatment with paclitaxel/ramucirumab vs other regimens
Study NCT02737787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1 Vaccine
Study NCT02737787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
Study NCT02737787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Vaccine
Description: Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.
Study NCT00986583 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Succinylcholine
Description: Succinylcholine will be administered pre-induction over a period of 5 seconds
Study NCT02908802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiotic
Study NCT02908802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Probiotics capsules without the active ingredient
Study NCT01052285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: UL-guided TAP block with 25 ml of ropivacaine 0,75% unilateral, single dose, ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline
Study NCT00083109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT00083109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00083109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suramin
Description: Given IV
Study NCT00002835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate (BLM)
Study NCT01052285 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: UL-guided Tap block with 25 ml of saline single dose Ilioinguinal block with 10 ml of saline and local infiltration with saline 40 ml single dose
Study NCT01052285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration
Description: Ilioinguinal block with 10 ml of ropivacaine 0,375% single dose, local infiltration with 40 ml of ropivacaine 0,375% single dose, UL-guided Tap block with 25 ml of saline single dose
Study NCT00002835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.
Study NCT00002835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Arm 1, Course 3, IV over 1 hour on day -6.
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP)
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (ARA-C)
Description: Arm 1, Course 3, every 12 hours on days -5 to -2.
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16)
Description: Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: During Course 1, IV continuously; Course 2, IV continuously on days 1-3.
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Study NCT01478750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: administration of fat (sunflower oil), emulsified
Description: 40 ml sunflower oil, in the presence of the emulsifier tween-80.
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT02253524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimenhydrinate
Description: 50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
Study NCT02253524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride (DHAD)
Description: Arm 1, Course 2, IV on day 1.
Study NCT00002835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Study NCT00002835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Infusion of stem cells on Day 0.
Study NCT01478750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of nasoduodenal tube
Description: A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
Study NCT00072189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV
Study NCT00072189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00072189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00002835 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy